- Home
- PRAA vs IMTX Comparison
PRAA vs IMTX Comparison
Compare PRAA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAA
- IMTX
- Stock Information
- Founded
- PRAA 1996
- IMTX N/A
- Country
- PRAA United States
- IMTX Germany
- Employees
- PRAA N/A
- IMTX N/A
- Industry
- PRAA Finance: Consumer Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRAA Finance
- IMTX Health Care
- Exchange
- PRAA Nasdaq
- IMTX Nasdaq
- Market Cap
- PRAA 619.5M
- IMTX 653.9M
- IPO Year
- PRAA N/A
- IMTX N/A
- Fundamental
- Price
- PRAA $15.79
- IMTX $6.00
- Analyst Decision
- PRAA Strong Buy
- IMTX Strong Buy
- Analyst Count
- PRAA 2
- IMTX 4
- Target Price
- PRAA $27.00
- IMTX $14.67
- AVG Volume (30 Days)
- PRAA 457.5K
- IMTX 662.2K
- Earning Date
- PRAA 08-04-2025
- IMTX 08-12-2025
- Dividend Yield
- PRAA N/A
- IMTX N/A
- EPS Growth
- PRAA N/A
- IMTX N/A
- EPS
- PRAA 1.79
- IMTX N/A
- Revenue
- PRAA $1,128,557,000.00
- IMTX $155,801,989.00
- Revenue This Year
- PRAA $2.73
- IMTX N/A
- Revenue Next Year
- PRAA $7.34
- IMTX $1.92
- P/E Ratio
- PRAA $8.89
- IMTX N/A
- Revenue Growth
- PRAA 25.02
- IMTX 93.56
- 52 Week Low
- PRAA $12.91
- IMTX $3.30
- 52 Week High
- PRAA $27.54
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- PRAA 56.18
- IMTX 61.02
- Support Level
- PRAA $15.25
- IMTX $5.50
- Resistance Level
- PRAA $16.41
- IMTX $6.17
- Average True Range (ATR)
- PRAA 0.62
- IMTX 0.28
- MACD
- PRAA 0.14
- IMTX 0.02
- Stochastic Oscillator
- PRAA 71.43
- IMTX 81.38
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.